Login to Your Account



Search

Search results

Pharma: Clinic roundup

Astrazeneca plc , of London, reported phase III data showing that the combination of saxagliptin/dapagliflozin, as a dual add-on therapy in adults with type 2 diabetes who were inadequately controlled on metformin, resulted in statistically significa ...

BioWorld Today - Staff - 2014-05-14 00:00 - 0 comments - 0 attachments

Clinic roundup

Basilea Pharmaceutica Ltd. , of Basel, Switzerland, reported that a phase III trial showed its antibiotic ceftobiprole to demonstrate more rapid clinical responses in hospital-acquired pneumonia and community-acquired pneumonia than a comparator regi ...

BioWorld Today - Staff - 2014-05-14 00:00 - 0 comments - 0 attachments

Clinic roundup

Amgen Inc. , of Thousand Oaks, Calif., and Astrazeneca plc , of London, reported that the phase III AMAGINE-1 study testing brodalumab, a drug designed to bind to the interleukin-17 receptor, in patients with moderate to severe plaque psoriasis me ...

BioWorld Today - Staff - 2014-05-13 00:00 - 0 comments - 0 attachments

Clinic roundup

Bind Therapeutics Inc. , of Cambridge, Mass., reported in its first quarter earnings call that a pre-specified evaluation of patients enrolled in its phase II non-small-cell lung cancer (NSCLC) trial with KRAS mutations showed that, of the six patien ...

BioWorld Today - Staff - 2014-05-12 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Pfizer Inc. , of New York, reported results from two phase II studies of bivalent rLP2086, its recombinant vaccine candidate in development for the prevention of invasive meningococcal disease caused by Neisseria meningitides serogroup B in subje ...

BioWorld Today - Staff - 2014-05-12 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Dompe Group , of Milan, reported preliminary phase I results confirming the tolerability of its recombinant human nerve growth factor (rhNGF), in development for ophthalmic use as a treatment for neurotrophic keratitis. (BioWorld-Today-2014- ...

BioWorld Today - Staff - 2014-05-09 00:00 - 0 comments - 0 attachments

Clinic roundup

Aicuris AG , of Wuppertal, Germany, and Merck & Co. Inc. , of Whitehouse Station, N.J., said phase II results were published in the New England Journal of Medicine showing the safety and efficacy of letermovir, an oral antiviral agent for ...

BioWorld Today - Staff - 2014-05-09 00:00 - 0 comments - 0 attachments

Clinic roundup

Epizyme Inc. , of Cambridge, Mass., said it started a phase Ib open-label study of EPZ-5676 in pediatric patients with acute leukemias bearing a rearrangement of the MLL gene (MLL-r). (BioWorld-Today-2014-05-08) ...

BioWorld Today - Staff - 2014-05-08 00:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Novartis AG , of Basel, Switzerland, presented results at the European Congress of Endocrinology in Wroclaw, Poland, from a pivotal phase III study of Signifor LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of c ...

BioWorld Today - Staff - 2014-05-07 00:00 - 0 comments - 0 attachments

Clinic roundup

Rhythm Pharmaceuticals Inc. , of Boston, presented phase II results at the Digestive Disease Week conference in Chicago showing that relamorelin, administered twice daily for four weeks in patients with moderate to severe gastroparesis, significant ...

BioWorld Today - Staff - 2014-05-07 00:00 - 0 comments - 0 attachments